Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT03780582 Active, not recruiting - Lung Cancer Clinical Trials

Evaluation of Use of Diagnostic AI for Lung Cancer in Practice

Start date: December 14, 2018
Phase: N/A
Study type: Interventional

This study investigates ways of improving radiologists performance of the classification of CT-scans as cancerous or non-cancerous. Participants interact with an AI to classify CT-scans under three different conditions.

NCT ID: NCT03773380 Completed - Lung Cancer Clinical Trials

Breathe Anew for Lung Cancer Survivorship

BA
Start date: January 2, 2019
Phase: Phase 1
Study type: Interventional

Survivorship programs have become an integral component of modern cancer care programs. In Canada, there has been tremendous success for survivorship programs for breast, prostate, and colorectal cancer, however lung cancer survivorship programs have not been widely developed. The complexity of the disease, high mortality, short survival times, high cost of surveillance, and patient habits have traditionally been barriers against the success of lung cancer survivorship programs. The investigator proposes a feasibility study to pilot a novel intervention titled Breathe Anew, which will aim to identify and overcome the barriers to the design and implementation of a lung cancer survivorship program. The investigator has assembled a multi-disciplinary team of experts and lung cancer survivors who will develop the Breathe Anew survivorship intervention. The intervention will be vetted using an integrated knowledge translation approach, which will involve members of the target population, primarily patients who previously underwent lung resection, to modify the intervention and ensure acceptability. After Breathe Anew has been designed, it will be tested in a pilot study of 50 patients to ensure its feasibility and determine its cost. The ultimate goal of this feasibility study is to lay the groundwork for a subsequent comparative trial to evaluate the impact of Breathe Anew on patient-important outcomes including health related quality and length of life and postoperative complications.

NCT ID: NCT03763851 Terminated - Breast Cancer Clinical Trials

Cannabis Oil and Radiation Therapy for the Management of Pain

Start date: March 14, 2018
Phase: Phase 2
Study type: Interventional

In this innovative approach seeking effective therapeutic strategies, the investigators are proposing to test the effectiveness of medical cannabis oil as an adjunct to palliative Radiation Therapy (RT) and Best Supportive Care to alleviate cancer pain that was only partially relieved with conventional medications. Furthermore, the investigators will assess the effect of medical cannabis oil on health-related quality of life and symptoms that are frequently associated with metastatic cancers including fatigue, anxiety, depression, insomnia and decreased appetite. The safety profile of medical cannabis oil with respect to prolonged use of more than two weeks of administration, concomitant medication use and palliative RT will also be examined.

NCT ID: NCT03755739 Recruiting - Breast Cancer Clinical Trials

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Start date: November 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.

NCT ID: NCT03755102 Completed - Lung Cancer Clinical Trials

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Start date: November 21, 2018
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.

NCT ID: NCT03753724 Completed - Lung Cancer Clinical Trials

IDEAL: Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis Study

IDEAL
Start date: August 29, 2018
Phase:
Study type: Observational

This study aims to test the use of novel CT image analysis techniques to enable a better characterisation of small pulmonary nodules. The study will incorporate solid and predominantly solid nodules of 5-15 mm scanned using a variety of scanner types, imaging protocols and patient populations. The investigators hope that the new image processing techniques will improve the accuracy of lung nodule analysis which will in turn reduce the number of unnecessary investigations for benign nodules and may increase the accuracy of the early diagnosis of lung cancer in malignant nodules. This study aims to test this novel analysis software to subsequently allow validation.

NCT ID: NCT03750864 Completed - Lung Cancer Clinical Trials

Innovative Approach to Reduce Lung Cancer Stigma

Start date: October 27, 2018
Phase: N/A
Study type: Interventional

This is a feasibility study examining the feasibility and acceptability of a novel psychotherapy intervention on lung cancer patients who are experiencing stigma.

NCT ID: NCT03747380 Completed - Lung Cancer Clinical Trials

Pre-operative Inspiratory Muscle Training Program to Prevent Pulmonary Complications After Thoracic Surgery

CT0076
Start date: January 7, 2019
Phase: N/A
Study type: Interventional

Postoperative pulmonary complications are the most common complications after thoracic surgery. In the literature, pulmonary complications after thoracic surgery are present in more than 37.5% of patients. No study investigates the impact of preoperative inspiratory muscle exercises program on pulmonary complications after thoracic surgery.

NCT ID: NCT03740256 Recruiting - Breast Cancer Clinical Trials

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

VISTA
Start date: December 14, 2020
Phase: Phase 1
Study type: Interventional

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. The study is looking at combining these two treatments together, because we think that the combination of treatments will work better than each treatment alone. We also hope to learn the best dose level of the treatments and whether or not it is safe to use them together. In this study, CAdVEC will be injected into participants tumor at one tumor site which is most easiest to reach. Once it infects the cancer cells, activation of the immune response will occur so it can attack and kill cancer cells. (This approach may have limited effects on the other tumor sites that have not received the oncolytic virus injection, so, patients will also receive specific T cells following the intratumor CAdVEC injection.) These T cells are special infection-fighting blood cells that can kill cells infected with viruses and tumor cells. Investigators want to see if these cells can survive in the blood and affect the tumor. Both CAdVEC and HER2-specific autologous CAR T are investigational products. They are not approved by the FDA.

NCT ID: NCT03739281 Terminated - Lung Cancer Clinical Trials

PET/MR Imaging in Lung Cancer

Start date: December 12, 2018
Phase: N/A
Study type: Interventional

The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.